This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Renal Hemodynamics and Tubular Function in Patients With Obstructive Sleep Apnea and Healthy Controls

This study has been completed.
Information provided by:
Regional Hospital Holstebro Identifier:
First received: December 10, 2006
Last updated: April 17, 2008
Last verified: April 2008

Nitrogen-oxide (NO) plays an important role for blood pressure regulation, renal hemodynamics, and the renal excretion of sodium. NO is synthesized from L-arginine in the vascular endothelium and have a very short half-life in plasma and is therefore very difficult to measure directly.

L-mono-methyl-L-arginine (L-NMMA) is an analogue to L-arginine and a competitive inhibitor of NO, and therefore can be used to study the effect of NO on the circulation. In normal subjects, infusion of L-NMMA will cause an increase in blood pressure, decreased renal plasma-flow, decreased glomerular filtration rate, and a decreased excretion of sodium.

Hypothesis: Patients with obstructive sleep apnea has a decreased activity in the NO-system. This is contributing to the hypertension often seen in these patients. Decreased activity in the NO-system can be revealed by diminished fall in renal hemodynamic and sodium excretion after infusion of L-NMMA.

Condition Intervention Phase
Obstructive Sleep Apnea Healthy Drug: L-NMMA (N-mono.methyl-L-arginine) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind
Primary Purpose: Basic Science

Resource links provided by NLM:

Further study details as provided by Regional Hospital Holstebro:

Estimated Enrollment: 40
Study Start Date: January 2005
Estimated Study Completion Date: November 2005

Ages Eligible for Study:   30 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Obstructive sleep apnea

Exclusion Criteria:

  • Drug or alcohol abuse
  • Pregnancy
  • Disease of the heart, lungs, liver, kidney or endocrine organs
  • Cerebral infarction
  • Diabetes
  • Gastrointestinal disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00410085

Department of Medical Research, Holstebro Hospital
Holstebro, Ringkoebing County, Denmark, 7500
Sponsors and Collaborators
Regional Hospital Holstebro
Study Chair: Erling B Pedersen, Professor Regional Hospital Holstebro
  More Information

Responsible Party: Pia H Gjørup, Department of Medical Research, Holstebro Hospital Identifier: NCT00410085     History of Changes
Other Study ID Numbers: MED.RES.HOS.2004.03.PHH
Study First Received: December 10, 2006
Last Updated: April 17, 2008

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases processed this record on July 19, 2017